Literature DB >> 11302547

Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation.

J A Hixon1, B R Blazar, M R Anver, R H Wiltrout, W J Murphy.   

Abstract

CD40 stimulation, by either antibody or ligand, has been shown to inhibit the growth of a variety of neoplastic cells, both in vivo and in vitro. In this study, we assessed the effects of CD40 stimulation using a murine agonistic CD40 monoclonal antibody (MoAb) (FGK115) or a soluble recombinant murine CD40 ligand (srmCD40L) in both lethally irradiated and nonirradiated BALB/c mice. Toxicity after CD40 stimulation was not observed in nonirradiated animals receiving up to 100 microg of the agonist anti-CD40 MoAb. However, as little as 10 microg of the agonistic anti-CD40 MoAb induced acute toxicity resulting in 100% morbidity of lethally irradiated animals by 4 days after irradiation. Histological evaluation of animals receiving anti-CD40 MoAb revealed severe intestinal lesions with disruption of the villi, goblet cell depletion, and crypt hyperplasia of the small intestine, colon, and cecum. Delaying the administration of anti-CD40 MoAb or reducing the amount of irradiation given resulted in increased survival and less severe lesions. Analysis of serum cytokine levels in lethally irradiated mice receiving agonistic anti-CD40 showed a marked increase of interferon (IFN)-gamma. Lethally irradiated IFN-gamma knockout mice given the agonistic anti-CD40 MoAb demonstrated significant increases in survival and minimal gut lesions compared with wild-type mice receiving the same regimen, suggesting that IFN-gamma plays a major role in this toxic reaction. These results indicate that CD40 stimulation using agonistic antibodies following lethal irradiation leads to a fatal, cytokine-induced disease affecting the intestine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11302547     DOI: 10.1053/bbmt.2001.v7.pm11302547

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  14 in total

1.  A potent adjuvant effect of CD40 antibody attached to antigen.

Authors:  Tom A Barr; Adele L McCormick; Jennifer Carlring; Andrew W Heath
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

2.  BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses.

Authors:  Hyun-Il Cho; Kelly Barrios; Young-Ran Lee; Angelika K Linowski; Esteban Celis
Journal:  Cancer Immunol Immunother       Date:  2012-12-25       Impact factor: 6.968

3.  Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule.

Authors:  Thomas R Kozel; Peter Thorkildson; Suzanne Brandt; William H Welch; Julie A Lovchik; David P AuCoin; Julpohng Vilai; C Rick Lyons
Journal:  Infect Immun       Date:  2006-10-23       Impact factor: 3.441

4.  Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.

Authors:  Ailsa J Christiansen; Alison West; Kellie-Marie Banks; Nicole M Haynes; Michele W Teng; Mark J Smyth; Ricky W Johnstone
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-22       Impact factor: 11.205

Review 5.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

6.  A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.

Authors:  Rich-Henry Schabowsky; Kutlu G Elpek; Shravan Madireddi; Rajesh K Sharma; Esma S Yolcu; Laura Bandura-Morgan; Robert Miller; Kathryn J MacLeod; Robert S Mittler; Haval Shirwan
Journal:  Vaccine       Date:  2009-10-29       Impact factor: 3.641

Review 7.  ProtEx technology for the generation of novel therapeutic cancer vaccines.

Authors:  Rich-Henry Schabowsky; Rajesh K Sharma; Shravan Madireddi; Abhishek Srivastava; Esma S Yolcu; Haval Shirwan
Journal:  Exp Mol Pathol       Date:  2009-01-31       Impact factor: 3.362

8.  mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia.

Authors:  Thomas R Kozel; William J Murphy; Suzanne Brandt; Bruce R Blazar; Julie A Lovchik; Peter Thorkildson; Ann Percival; C Rick Lyons
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

9.  Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Cristina M Lu; Elaine B Brooks; Richard E Fichtl; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.

Authors:  Rajesh K Sharma; Kutlu G Elpek; Esma S Yolcu; Rich-Henry Schabowsky; Hong Zhao; Laura Bandura-Morgan; Haval Shirwan
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.